文献速递泌尿生殖与妇科肿瘤放疗

前列腺立体定向放疗后活检结局的预测因素

Predictors for post-treatment biopsy outcomes after prostate stereotactic body radiotherapy.
PubMed 文献 · Radiother Oncol · 2021-02-13

研究纳入257例接受5–6次前列腺SBRT、剂量32.5 Gy至>40 Gy的局限期前列腺癌患者,治疗后约两年行活检评估局部控制。阳性、阴性和治疗效应活检发生率分别为15.6%、57.6%和26.8%;多因素模型显示SBRT剂量<40 Gy及不利中间危或高危患者阳性活检可能性更高,阳性活检与五年PSA复发风险显著升高相关。

要点

  • SBRT剂量≥40 Gy时两年活检显示极佳肿瘤控制。
  • 标准SBRT剂量35–37.5 Gy与阳性活检可能性升高相关。
  • 两年阳性活检多数先于PSA失败出现。

核心结论

  • 基于两年活检,SBRT剂量≥40 Gy时获得极佳肿瘤控制;标准剂量35–37.5 Gy与阳性活检可能性升高相关;两年阳性活检多数先于PSA失败出现。

研究设计与样本

  • 257例局限期前列腺癌患者接受前列腺SBRT,剂量32.5 Gy至>40 Gy,分5–6次,治疗后约两年行活检评估局部控制状态。
  • 风险分组:73%为中间危(n=187),17%为低危(n=43),10%为高危(n=27)。

主要发现

  • 阳性、阴性和治疗效应活检发生率分别为15.6%、57.6%和26.8%。
  • 按剂量阳性活检发生率:32.5 Gy为37.5%(n=9/24),35 Gy为21.4%(n=6/28),37.5 Gy为19.4%(n=6/31),>40 Gy为10.9%(n=19/174)。
  • 多因素模型中,SBRT剂量<40 Gy及不利中间危或高危患者阳性活检可能性更高。
  • 阳性活检者五年PSA复发可能性显著更高:57%(95% CI: 29-77%)对比阴性活检7%(95% CI: 3-14%),p < 0.001。

关键数值与推荐

  • SBRT剂量≥40 Gy与极佳肿瘤控制相关。
  • 标准SBRT剂量35–37.5 Gy与阳性活检可能性升高相关。
  • 两年阳性活检者五年PSA复发率为57%(95% CI: 29-77%),阴性活检者为7%(95% CI: 3-14%),p < 0.001。

临床怎么用

  • 前列腺癌SBRT应优先考虑≥40 Gy剂量以降低阳性活检风险。
  • 对接受35–37.5 Gy标准剂量或不利中间危/高危患者,应加强治疗后监测。
  • 两年阳性活检提示后续PSA失败风险高,可据此提前干预或密集随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate predictors associated with post-treatment biopsy outcomes after stereotactic body radiotherapy (SBRT) for localized prostate cancer. MATERIALS AND METHODS: 257 patients treated with prostate SBRT to dose levels of 32.5 Gy to >40 Gy in 5-6 fractions underwent a post-treatment biopsy performed approximately two years after treatment to evaluate local control status. 73 had% intermediate-risk disease (n = 187) and the remaining 17% (n = 43) and 10% (n = 27) had low-risk and high-risk disease, respectively. RESULTS: The incidence of positive, negative, and treatment-effect post-treatment biopsies were 15.6%, 57.6%, and 26.8%, respectively. The incidence of a positive biopsy according to dose was 37.5% (n = 9/24), 21.4% (n = 6/28), 19.4% (n = 6/31), and 10.9% (n = 19/174) for 32.5 Gy, 35 Gy, 37.5 Gy, and >40 Gy, respectively. In a multivariable model, patients treated with SBRT doses of <40 Gy and those with unfavorable-intermediate-risk or high-risk disease had higher likelihood of a positive post-treatment biopsy. A positive post-SBRT biopsy was associated with a significantly higher likelihood of subsequent PSA relapse at five years (Positive biopsy: 57%, 95% CI: 29-77% compared to negative biopsy: 7%, 95% CI: 3-14%; p < 0.001). CONCLUSION: Based on two-year post-SBRT biopsies, excellent tumor control was achieved when dose levels of 40 Gy or higher were used. Standard SBRT dose levels of 35-37.5 Gy were associated with a higher likelihood of a positive post-treatment biopsy. Two-year positive post-treatment biopsies pre-dated the development of PSA failure in the majority of patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Zelefsky MJ, Goldman DA, Hopkins M, et al. Predictors for post-treatment biopsy outcomes after prostate stereotactic body radiotherapy. Radiother Oncol. 2021. PMID: 33587971. doi:10.1016/j.radonc.2021.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。